$0.16
(Market cap
$4 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
0.7
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
0.1
-
Debt to Equity
0
-
Book Value
$1.5
-
EPS
$-2.8
-
Face value
--
-
Shares outstanding
1,816,565
10 Years Aggregate
CFO
$-22.81 Mln
EBITDA
$-18.60 Mln
Net Profit
$-17.06 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
XORTX Therapeutics (XRTX)
| -17.8 | 8.5 | 4.1 | -44.3 | -90.3 | -35.7 | -- |
|
BSE Sensex*
| -10.2 | -3.7 | 2.5 | -5.8 | 4.9 | 5.5 | 10.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2021
|
2020
|
|---|---|---|---|---|---|
|
XORTX Therapeutics (XRTX)
| -50.2 | -50.8 | -99.6 | 1,667.2 | -11.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 22.0 | 15.8 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
XORTX Therapeutics (XRTX)
|
2.3 | 4.2 | 0.0 | -3.8 | -- | -98.9 | -- | 0.7 |
| 3.2 | 326.3 | 56.6 | -65.4 | -131.8 | -111.7 | -- | 8.2 | |
| 13.5 | 846.5 | 0.0 | -175.9 | -- | -106.8 | -- | 5.3 | |
| 14.1 | 2,449.0 | 549.1 | 17.9 | -6.3 | 1.4 | 140.9 | 1.7 | |
| 17.3 | 2,249.1 | 120.8 | -57.8 | -42.6 | -9.9 | -- | 3.9 | |
| 11.2 | 794.8 | 366.5 | 9.3 | 8.3 | 3.4 | 80.2 | 2.9 | |
| 3.7 | 671.1 | 4.1 | -187.9 | -4,613.1 | -233.9 | -- | 0.3 | |
| 14.6 | 906.8 | 0.6 | -60.0 | -9,892.6 | -119 | -- | 23.9 | |
| 6.9 | 653.3 | 143.5 | -158.2 | -80.2 | -168.9 | -- | 6.6 | |
| 26.2 | 2,944.7 | 449.6 | -188.2 | -41.1 | -28.5 | -- | 4.9 |
Shareholding Pattern
View DetailsAbout XORTX Therapeutics (XRTX)
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat hyperuricemia related diseases in Canada. It develops XRx-026, which is in Phase III for the treatment of... gout; XRx-008, which is in Phase II for the treatment of autosomal dominant polycystic kidney disease; XRx-101, which is in Phase II for the treatment of acute kidney injury associated with respiratory virus infection, including sepsis and coronavirus; and XRX-225, which is in preclinical stage for the treatment of type 2 diabetic nephropathy, as well as VB4-P5, a program for the treatment and prevention of fibrosis in the kidney. The company is based in Calgary, Canada. Read more
-
Founder, CEO, President & Director
Dr. Allen Warren Davidoff Ph.D.
-
Founder, CEO, President & Director
Dr. Allen Warren Davidoff Ph.D.
-
Headquarters
Calgary, AB
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for XORTX Therapeutics (XRTX)
What is the current share price of XORTX Therapeutics Inc (XRTX) Today?
The share price of XORTX Therapeutics Inc (XRTX) is $2.31 (NASDAQ) as of 04-Sep-2026 16:00 EDT. XORTX Therapeutics Inc (XRTX) has given a return of -90.28% in the last 3 years.
What is the current PB & PE ratio of XORTX Therapeutics Inc (XRTX)?
Since, TTM earnings of XORTX Therapeutics Inc (XRTX) is negative, P/E ratio is not available.
The P/B ratio of XORTX Therapeutics Inc (XRTX) is 0.71 times as on 04-Sep-2026, a 86 discount to its peers’ median range of 4.90 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-0.28 |
0.35 |
2024 |
-0.05 |
0.04 |
2023 |
-0.09 |
0.04 |
2022 |
-0.04 |
0.07 |
2021 |
-0.61 |
0.08 |
What is the 52 Week High and Low of XORTX Therapeutics Inc (XRTX)?
The 52-week high and low of XORTX Therapeutics Inc (XRTX) are Rs 7.05 and Rs 1.73 as of 07-Sep-2026.
What is the market cap of XORTX Therapeutics Inc (XRTX)?
XORTX Therapeutics Inc (XRTX) has a market capitalisation of $ 4 Mln as on 04-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in XORTX Therapeutics Inc (XRTX)?
Before investing in XORTX Therapeutics Inc (XRTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.